Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study
Mazyar Shadman(University of Washington), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Brian T. Hill(Cleveland Clinic), Lori A. Leslie(Hackensack University Medical Center), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Alan P Skarbnik(Novant Health), Jennifer R. Brown(Dana-Farber Cancer Institute), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Rebecca Burne, John N. Allan(Cornell University), Nnadozie Emechebe(AbbVie (United States)), Rajesh Kamalakar(AbbVie (United States)), Danielle M. Brander(Duke University), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Kavita Sail(AbbVie (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), Paul M. Barr(University of Rochester Medical Center), Irina Pivneva(Analysis Group (United States)), Annie Guerin, Matthew S. Davids(Dana-Farber Cancer Institute), Hande H. Tuncer(Tufts Medical Center), Beenish S. Manzoor(AbbVie (United States)), Anna Schuh(University of Oxford), Alexandros Rampotas(London Cancer), Chaitra S. Ujjani(Fred Hutch Cancer Center), Stephen J. Schuster(Hospital of the University of Pennsylvania), Barbara Eichhorst(University of Cologne), Hasan Alhasani(AbbVie (United States)), Isabelle Fleury(Hôpital Maisonneuve-Rosemont), Dingfeng Jiang(AbbVie (United States)), Rajat Bannerji(Rutgers, The State University of New Jersey)
Cited by 16
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k